Abstract
BackgroundSurveillance for adverse events following immunization is an important component of any national immunization programme because it is critical to assessing the safety of vaccines and to detecting potentially rare and severe adverse events and responding in a timely manner. We conducted an enhanced active surveillance aimed at assessing the safety of flu vaccines in the 2015–2016 season in Italy. The study was targeted to the population groups for which the seasonal vaccine is recommended in Italy.MethodsDuring the study period, a total of 3213 individuals receiving seasonal influenza vaccination were registered on the web-based platform. Any adverse events experienced after 7 days from vaccination by individuals aged six months or more were collected through a telephone interview or by a web-based self-administered questionnaire. All individuals experiencing at least one event during the 7 days of follow-up were contacted for follow-up to 60 days.ResultsOverall, 854 events were reported: 845 events (26%) after administration of the first dose and 9 (12%) after the second dose. The majority of adverse events reported after 7 days from the first dose were of little clinical importance, and most involved local symptoms.ConclusionOur data, even though the number of vaccinated individuals was smaller than expected, is consistent with the safety of influenza vaccines in Italy during the 2015–2016 season regarding the most common adverse events. Further efforts are needed to obtain sufficient power to study rarer adverse events. Active monitoring and systematic studies to test generated signals and hypotheses are crucial to intensify awareness among the public and professionals with regard to the safety of vaccines.
Highlights
Surveillance for adverse events following immunization is an important component of any national immunization programme because it is critical to assessing the safety of vaccines and to detecting potentially rare and severe adverse events and responding in a timely manner
This paper presents findings from a study conducted during the 2015–2016 season in Italy, targeted to the population group for which the influenza vaccine is recommended and aimed at implementing enhanced surveillance to evaluate influenza vaccine safety
After 7 days, all parents and vaccinated individuals were asked to communicate any adverse events following immunization (AEFI) reported in their diary during a telephone interview
Summary
Surveillance for adverse events following immunization is an important component of any national immunization programme because it is critical to assessing the safety of vaccines and to detecting potentially rare and severe adverse events and responding in a timely manner. We conducted an enhanced active surveillance aimed at assessing the safety of flu vaccines in the 2015–2016 season in Italy. The study was targeted to the population groups for which the seasonal vaccine is recommended in Italy. Influenza is a major public health problem; a conservative estimate suggests that the illness infects every third child and every tenth adult, annually 60 million of the 500 million inhabitants of the European Union. In Italy, seasonal influenza vaccination is recommended and provided free of charge to the elderly (≥ 65 years) and to people aged 6 months to 64 years with comorbidities that increase the risk of influenza complications and to those in other categories (e.g., pregnant women in the second and third trimester, health care workers, etc.) [8].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
